The knockdown of lipin-1 or the inhibition of its PAP activity by propranolol sensitized breast and prostate cancer cells to the inhibition of mTORC1 by rapamycin, hence providing experimental evidence that lipin-1 represents a potential target for cancer treatments [36]. The gene discussed is LPIN1; the disease is prostate cancer.